Hims & Hers Health, Inc.
Bear Case (25th pct.)
-164.1% vs price
Base Case (Median)
-86.2% vs price
Bull Case (75th pct.)
-71.0% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $-69.15 | -352.5% | High (40%) |
| EV/EBITDA | $7.93 | -71.0% | Medium (20%) |
| EV/FCF | $7.99 | -70.8% | Medium (20%) |
| Earnings Power Value | $-0.36 | -101.3% | Medium (50%) |
Based on 4 out of 8 methods, HIMS appears overvalued at the current price of $27.39. The base case fair value of $3.79 implies 86.2% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.